ChinaHealthcare and life sciences2019 – ongoingHansoh Pharma
AtomNet screening for difficult oncology targets
Hansoh reported active anticancer compounds from its initial Atomwise collaboration
Problem
Hansoh sought active compounds against oncology targets that had proved difficult for drug discovery.
Approach
Hansoh began collaborating with Atomwise in November 2019. Atomwise used its deep-learning AtomNet platform to screen molecules against multiple oncology targets. Hansoh reported several active anticancer compounds from the initial work and expanded the partnership in April 2020.
Results
No published figures
Takeaway
The reported result concerned early compound discovery. It did not establish clinical efficacy or an approved medicine from the collaboration.
Categories
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Process innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Partner co-development
- Evidence
- Company's own claim
Sources
Source summaries
Hansoh reported that its initial Atomwise collaboration identified several active anticancer compounds against a challenging target. The expanded relationship continued AtomNet screening across oncology targets.
Full details are in the original sources.